Spinal Muscular Atrophy Trial, Recruiting (NCT05724173)

Spinal Muscular Atrophy Trial, Recruiting NCT05724173 Sponsor: Leigh R. Hochberg, MD, PhD. Condition: Spinal Muscular Atrophy

Printed from Voxsanity (voxsanity.com.au) — NCT05724173 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Spinal Muscular Atrophy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are between 18 and 80 years old.
You have been diagnosed with ALS (a condition affecting the nerve cells that control muscles), confirmed by a specialist in neurological diseases.
You have ALS and have completely lost the ability to speak, or have severely reduced speech that has been getting worse over the past four months.
You live within a three-hour drive of the study location and are able to stay in the same area for at least 15 months after joining the trial.

Who may not be able to join:

You have a vision problem that would make it difficult to look at a computer screen for extended periods of time, even with glasses or contact lenses.
You are currently taking steroids or medicines that suppress your immune system, either by mouth or through a drip, on a long-term basis.
You have another serious illness or condition that could affect your ability to take part in the study.
There may be additional reasons that could prevent you from joining — please confirm the full list directly with the trial site.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jaimie Henderson, MD, Stanford University

Phone: 617-724-9247

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05724173

Sponsor: Leigh R. Hochberg, MD, PhD.

Phase: Not Applicable

Status: Recruiting

Condition: Spinal Muscular Atrophy

Trial contact: 617-724-9247

More information: https://clinicaltrials.gov/study/NCT05724173

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are between 18 and 80 years old.
You have been diagnosed with ALS (a condition affecting the nerve cells that control muscles), confirmed by a specialist in neurological diseases.
You have ALS and have completely lost the ability to speak, or have severely reduced speech that has been getting worse over the past four months.
You live within a three-hour drive of the study location and are able to stay in the same area for at least 15 months after joining the trial.

Who may not be able to join:

You have a vision problem that would make it difficult to look at a computer screen for extended periods of time, even with glasses or contact lenses.
You are currently taking steroids or medicines that suppress your immune system, either by mouth or through a drip, on a long-term basis.
You have another serious illness or condition that could affect your ability to take part in the study.
There may be additional reasons that could prevent you from joining — please confirm the full list directly with the trial site.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Leigh R. Hochberg, MD, PhD.

Registry

ClinicalTrials.gov

Start date

18 October 2023

Est. completion

31 July 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Device Safety

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov